Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The first cardiovascular safety trial of a GLP-1R agonist, demonstrating that lixisenatide does not augment MACE in patients with T2DM who had a recent acute coronary event
The burden falls entirely on the individual to recognize problems and seek help
A focused, one-target design Melanotan I mainly flips on the skin's pigment switch, without needing sun exposure to kick it into gear
About Ergomax
Opportunity Growing Research and Development The future of the GLP-1 receptor agonist market is promising, driven by growing research and development activities
US$ 25.53
US$ 25.29
US$ 29.47
US$ 26.74
